Fibronectin- and vitronectin-induced microglial activation and matrix metalloproteinase-9 expression is mediated by integrins α 5β1 and αvβ5

Journal of Immunology

Volumn 178, Issue 12, 2007, Pages 8158-8167

  Milner, Richard ^a   Crocker, Stephen J ^a   Hung, Stephanie ^a   Wang, Xiaoyun ^a   Frausto, Ricardo F ^a   Del Zoppo, Gregory J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; FIBRONECTIN; GELATIN; GELATINASE B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DEMYELINATION; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM;

EID: 34250205287     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.12.8158     Document Type: Article

References (95)

1. Carson, M. J. 2002. Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 40: 218-231.
2. Kreutzberg, G. W. 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19: 312-318.
3. Raivich, G., M. Bohatschek, C. U. Kloss, A. Werner, L. L. Jones, and G. W. Kreutzberg. 1999. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Brain Res. Rev. 30: 77-105.
4. Barnett, M. H., and J. W. Prineas. 2004. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55: 458-468.
5. Gonzalez-Scarano, F., and G. Baltuch. 1999. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22: 219-240.
6. Hickey, W. F. 1999. The pathology of multiple sclerosis: a historical perspective. J. Neuroimmunol. 98: 37-44.
7. Ransohoff, R. M. 1999. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J. Neuroimmunol. 98: 57-68.
8. Trapp, B. D., L. Bo, S. Mork, and A. Chang. 1999. Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 98: 49-56.
9. Wahl, L. M., and M. L. Corcoran. 1993. Regulation of monocyte/macrophage metalloproteinase production by cytokines. J. Periodontol. 64: 467-473.
10. Opdenakker, G., P. E. Van den Steen, and J. Van Damme. 2001. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22: 571-579.
11. Rosenberg, G. A. 2002. Matrix metalloproteinases in neuroinflammation. Glia 39: 279-291.
12. Anthony, D. C., B. Ferguson, M. K. Matyzak, K. M. Miller, M. Esiri, and V. H. Perry. 1997. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropath. App. Neurobiol. 23: 406-415.
13. Cossins, J. A., J. Clements, M. J. Ford, K. M. Miller, R. Pigott, W. Vos, P. Van der Valk, and C. J. de Groot. 1997. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropath. 94: 590-598.
14. Maeda, A., and R. A. Sobel. 1996. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropath. Exp. Neurol. 55: 300-309.
15. Dubois, B., S. Masure, U. Hurtenbach, L. Paemen, H. Heremans, J. van den Oord, R. Sciot, T. Meinhardt, G. Hammerling, G. Opdenakker, and B. Arnold. 1999. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104: 1507-1515.
16. Yong, V. W., C. Power, P. Forsyth, and D. R. Edwards. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2: 502.
17. Proost, P., J. Van Damme, and G. Opdenakker. 1993. Leukocyte gelatinase B cleavage releases encephalitogens form human myelin basic protein. Biochem. Biophys. Res. Comm. 192: 1175-1181.
18. Chandler, S., R. Coats, A. J. Gearing, J. Lury, G. Wells, and E. Bone. 1995. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201: 223-226.
19. Gu, Z., M. Kaul, B. Yan, S. J. Kridel, J. Cui, A. Strongin, J. W. Smith, R. C. Liddington, and S. A. Lipton. 2002. S-Nitrosylation of matrix metalloproteinases: signaling pathways to neuronal cell death. Science 297: 1186-1190.
20. Lee, S. R., K. Tsuiji, and E. H. Lo. 2004. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J. Neurosci. 24: 671-678.
21. Ballabh, P., A. Braun, and M. Nedergaard. 2004. The blood-brain barrier: an overview: structure, regulation and clinical implications. Neurobiol. Dis. 16: 1-13.
22. del Zoppo, G. J., and T. Mabuchi. 2003. Cerebral microvessel responses to focal ischemia. J. Cereb. Blood Flow Metab. 23: 879-894.
23. del Zoppo, G. J., and R. Milner. 2006. Integrin-matrix interactions in the cerebral microvasculature. Arterioscler. Thromb. Vasc. Biol. 26: 1966-1975.
24. Gay, D., and M. Esiri. 1991. Blood-brain barrier damage in acute multiple sclerosis plaques. Brain 114: 557-572.
25. Kirk, J., J. Plumb, M. Mirakhur, and S. McQuaid. 2003. Tight junction abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination, J. Pathol. 201: 319-327.
26. Hamann, G. F., Y. Okada, and G. J. del Zoppo. 1996. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia. J. Cereb. Blood Flow Metab. 16: 1373-1378.
27. Sobel, R., M. Chen, A. Maeda, and J. Hinojoza. 1995. Vitronectin and integrin vitronectin receptor localisation in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 54: 202-213.
28. Sobel, R. A. 1998. The extracellular matrix in multiple sclerosis lesions. J. Neuropath. Exp. Neurol. 57: 205-217.
29. Sobel, R. A., and M. E. Mitchell. 1989. Fibronectin in multiple sclerosis lesions. Am. J. Pathol. 135: 161-169.
30. Adams, J. C. and F. M. Watt. 1993. Regulation of development and differentiation by the extracellular matrix. Development 117: 1183-1198.
31. Milner, R., and I. L. Campbell. 2002. The integrin family of cell adhesion molecules has multiple functions within the CNS. J. Neurosci. Res. 69: 286-291.
32. Sheppard, D. 2000. In vivo functions of integrins: lessons from null mutations in mice. Matrix Biol. 19: 203-209.
33. Springer, T. A. 1990. Adhesion receptors of the immune system. Nature 346: 425-434.
34. Sastry, S. K., and A. F. Horwitz. 1993. Integrin cytoplasmic domains: mediators of cytoskelelal linkages and extra- and intracellular initiated transmembrane signaling. Curr. Opin. Cell Biol. 5: 819-831.
35. Hynes, R. O. 2002. Integrins: bidirectional allosteric signaling machines. Cell 110: 673-687.
36. Giancotti, F. G., and E. Ruoslahti. 1999. Integrin signaling. Science 285: 1028-1032.
37. Diamond, M. S., and T. A. Springer. 1994. The dynamic regulation of integrin adhesiveness. Curr. Biol. 4: 506-517.
38. Milner, R., and I. L. Campbell. 2003. The extracellular matrix and cytokines regulate microglial integrin expression and activation. J. Immunol. 170: 3850-3858.
39. Crocker, S. J., J. K. Whitmire, R. F. Frausto, P. Chertboonmuang, P. D. Soloway, J. L. Whitton, and I. L. Campbell. 2006. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1- deficient mice. Am. J. Pathol. 169: 2104-2116.
40. 1 integrins during angiogenesis in the central nervous system. Mol. Cell. Neurosci. 20: 616-626.
41. 1 integrin. J. Neurosci. 22: 1562-1572.
42. Heo, J. H., J. Lucero, T. Abumiya, J. A. Koziol, B. R. Copeland, and G. J. del Zoppo. 1999. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 19: 624-633.
43. Maier, J., C. L. Kincaid, A. Pagenstecher, and I. L. Campbell. 2002. Regulation of signal transducer and activator of transcription (STAT) and suppressor of cytokine signaling (SOCS) gene expression in the brain of mice with astrocyte-targeted production of IL-12 and experimental autoimmune encephalomyelitis. Am. J. Pathol. 160: 271-288.
44. von Budingen, H.-C., N. Tanuma, P. Villoslada, J.-C. Ouallet, S. L. Hauser, and C. P. Genain. 2001. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J. Clin. Immunol. 21: 155-170.
45. Teesalu, T., A. E. Hinkkanen, and A. Vaheri. 2001. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am. J. Pathol. 159: 2227-2237.
46. Kauppinen, T. M., and R. A. Swanson. 2005. Poly (ADP-ribose) polymerase-1 promotes microglial activation, proliferation and matrix metalloproteinase-9- mediated neuron death. J. Immunol. 174: 2288-2296.
47. Liuzzi, G. M., M. P. Santaeroce, W. J. Peumans, E. J. Van Damme, B. Dubois, G. Opdenakker, and P. Riccio. 1999. Regulation of gelatinases in microglia and astrocyte cell cultures by plant lectins. Glia 27: 53-61.
48. Muir, E. M., K. H. Adcock, D. A. Morgenstern, R. Clayton, N. von Stillfried, K. Rhodes, C. Ellis, J. W. Fawcett, and J. H. Rogers. 2002. Matrix metalloproteinases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res. Mol. Brain Res. 100: 103-117.
49. Arai, K., S. R. Lee, and E. H. Lo. 2003. Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 43: 254-264.
50. Oh, L. Y., P. H. Larsen, C. A. Krekowski, D. R. Edwards, F. Donovan, Z. Werb, and V. W. Yong. 1999. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 19: 8464-8475.
51. Larsen, P. H., A. G. DaSilva, K. Conant, and V. W. Yong. 2006. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 26: 2207-2214.
52. Larsen, P. H., J. E. Wells, W. B. Stalłcup, G. Opdenakker, and V. W. Yong. 2003. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 23: 11127-11135.
53. Gebicke-Haerter, P. J., J. Bauer, A. Schobert, and H. Northoff. 1989. Lipopolysaccharide-free conditions in primary astrocyte cultures allow growth and isolation of microglial cells. J. Neurosci. 9: 183-194.
54. Purves, L. R., G. Brown, and N. Linton. 1982. Fibronectin levels in normal subjects and patients admitted to a respiratory intensive care unit. S. Afr. Med. J. 61: 733-736.
55. Felding-Habermann, B., and D. A. Cheresh. 1993. Vitronectin and its receptors. Curr. Opin. Cell Biol. 5: 864-868.
56. Kleiner, D. E., and W. G. Stetler-Stevenson. 1994. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218: 325-329.
57. Leber, T. M., and F. R. Balkwill. 1997. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal. Biochem. 249: 24-28.
58. Kloss, C. U., M. Bohatschek, G. W. Kreutzberg, and G. Raivich. 2001. Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in the mouse brain and in cell culture. Exp. Neurol. 168: 32-46.
59. Huber, J. D., R. D. Egleton, and T. P. Davis. 2001. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neourosci. 24: 719-725.
60. Okada, Y., B. R. Copeland, R. Fitridge, J. A. Koziol, and G. J. del Zoppo. 1994. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 25: 1847-1853.
61. Mabuchi, T., K. Kitagawa, T. Ohtsuki, K. Kuwabara, Y. Yagita, T. Yanagihara, M. Hori, and M. Matsumoto. 2000. Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 31: 1735-1743.
62. Meda, L., M. A. Cassatella, G. I. Szendrei, L. J. Otovos, P. Baron, M. Villalba, D. Ferrari, and F. Rossi. 1995. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 374: 647-650.
63. Risau, W., and V. Lemmon. 1988. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev. Biol. 125: 441-450.
64. Venstrom, K. A., and L. F. Reichardt. 1993. Extracellular matrix 2: role of extracellular matrix molecules and their receptors in the nervous system. FASEB J. 7: 996-1003.
65. Niquet, J., I. Jorquera, Y. Ben-Ari, and A. Represa. 1994. Proliferative astrocytes may express fibronectin-like protein in the hippocampus of epileptic rats. Neurosci. Lett. 180: 13-16.
66. Niquet, J., A. Gillian, Y. Ben-Ari, and A. Represa. 1996. Reactive glial cells express a vitronectin-like protein in the hippocampus of epileptic rats. Glia 16: 359-367.
67. Hoffman, K. B., J. K. Pinkstaff, C. Gall, and G. Lynch. 1998. Seizure induced synthesis of fibronectin is rapid and age dependent: implications for long-term potentiation and sprouting. Brain Res. 812: 209-215.
68. Rucklidge, G. J., V. Dean, S. P. Robins, O. Mella, and R. Bjerkvig. 1989. Immunolocalization of extracellular matrix proteins during brain tumor invasion in BD IX rats. Cancer Res. 49: 5419-5423.
69. Rutka, J. T., C. A. Myatt, J. R. Giblin, R. L. Davis, and M. L. Rosenblum. 1987. Distribution of extracellular matrix proteins in primary human brain tumours: an immunohistochemical analysis. Can. J. Neurol Sci. 14.
70. Arrihas, J. 2005. Matrix metalloproteinases and tumor invasion. N. Engl. J. Med. 352: 2020-2021.
71. Lo, E. H., X. Wang, and M. L. Cuzner. 2002. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69: 1-9.
72. Chandler, S., J. Cossins, J. Lury, and G. Wells. 1996. Macrophage elastase degrades matrix and myelin proteins and processes a tumour necrosis factor-α fusion protein. Biochem. Biophys. Res. Comm. 228: 421-429.
73. Mandler, R. N., J. D. Dencoff, F. Midani, C. C. Ford, W. Ahmed, and G. A. Rosenberg. 2001. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 124: 493-498.
74. Gijbels, K., S. Masure, H. Carton, and G. Opdenakker. 1992. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41: 29-34.
75. Gijbels, K., R. E. Galardy, and L. Steinman. 1994. Reversal of experimental autoimmune encephalomyelitis with a hydroxymate inhibitor of matrix metalloproteinases. J. Clin. Invest. 94: 2177-2182.
76. Hewson, A. K., T. Smith, J. P. Leonard, and M. L. Cuzner. 1995. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinases inhibitor Ro31-9790. Inflamm. Res. 44: 345-349.
77. Anthony, D. C., K. M. Miller, S. Feam, M. J. Townsend, G. Opdenakker, G. M. Wells, J. Clements, M. S. Chandler, A. J. Gearing, and V. H. Perry. 1998. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol. 87: 62-72.
78. Gidday, J. M., Y. G. Gasche, J. C. Copin, A. R. Shah, R. S. Perez, S. D. Shapiro, P. H. Chan, and T. S. Park. 2005. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. 289: H558-H568.
79. Kelly, M. A., A. Shuaib, and K. G. Todd. 2006. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp. Neurol. 200: 38-49.
80. Colognato, H., W. Baron, V. Avellana-Adalid, J. B. Relvas, A. Baron-Van Evercooren, E. Georges-Labouesse, and C. ffrench-Constant. 2002. CNS integrins switch growth factor signalling to promote target-dependent survival. Nat. Cell Biol. 4: 833-841.
81. O'Connell, J. P., F. Willenbrock, A. J. Docherty, D. Eaton, and G. Murphy. 1994. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J. Biol. Chem. 269: 14967-14973.
82. Ogata, Y., Y. Itoh, and H. Nagase. 1995. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinase-1 complex by 4-aminophenylmercuric acetate and proteinases. J. Biol. Chem. 270: 18506-18511.
83. Toth, M., I. Chvyrkova, M. M. Bernardo, S. Hernandez-Barrantes, and R. Fridman. 2003. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem. Biophys. Res. Comm. 308: 386-395.
84. Ramos-DeSimone, N., E. Hahn-Dantona, J. Sipley, H. Nagase, D. L. French, and J. P. Quigley. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274: 13066-13076.
85. Kim, Y. S., S. S. Kim, J. J. Cho, D. H. Choi, O. Hwang, D. H. Shin, H. S. Chun, M. F. Beal, and T. H. Joh. 2005. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25: 3701-3711.
86. Crocker, S. J., R. Milner, N. Pham-Mitchell, and I. L. Campbell. 2006. Cell and agonist-specific regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial cells. J. Neurochem. 98: 812-823.
87. Ullrich, O., A. Diestel, I. Y. Eyupoglu, and R. Nitsch. 2001. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-I. Nat. Cell Biol. 3: 1035-1042.
88. Witting, A., P. Muller, A. Herrmann, H. Kettenmann, and C. Nolte. 2000. Phagocytic clearance of apoptotic neurons by microglia/brain macrophages in vitro: involvement of lectin-, integrin-, and phosphatidylserine-mediated recognition. J. Neurochem. 75: 1060-1070.
89. Bi, X., C. M. Gall, J. Zhou, and G. Lynch. 2002. Uptake and pathogenic effects of amyloid β peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112: 827-840.
90. Miceli, M. V., D. A. Newsome, and D. J. J. Tate. 1997. Vitronectin is responsible for serum-stimulated uptake of rod outer segments by cultured retinal pigment epithelial cells. Invest. Opthalmol. Vis. Sci. 38: 1588-1597.
91. 5 integrin for binding but not for internalization. Proc. Natl. Acad. Sci. USA 94: 12932-12937.
92. 5 binding and cytoskeletal linkage. J. Exp. Med. 190: 861-874.
93. 5 integrin. J. Exp. Med. 200: 1539-1545.
94. Bo, L., S. Mork, P. A. Kong, H. Nyland, C. A. Pardo, and B. D. Trapp. 1994. Detection of MHC class II antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J. Neuroimmunol. 51: 135-146.
95. 2 integrin LFA-1 in multiple sclerosis lesions. J. Neuropath. Exp. Neurol. 55: 1060-1072.